Crescendo CEO says Takeda’s decision to exercise licence option is validation of its immunotherapy platform

Crescendo CEO says Takeda’s decision to exercise licence option is validation of its immunotherapy platform

APM Health Europe

Multifunctional Humabody Biologics for Immune-Oncology, Based on In Vivo Matured Fully Human VH

Multifunctional Humabody Biologics for Immune-Oncology, Based on In Vivo Matured Fully Human VH (PEGS 2018 poster)

View Poster

Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody®

Crescendo Biologics announces early licensing by Takeda
of first oncology-targeted Humabody®

View PDF

Crescendo Biologics wins “Biotech Company of the Year” at the Cambridge Independent Science and Technology Awards 2018

Crescendo Biologics wins “Biotech Company of the Year” at the Cambridge Independent Science and Technology Awards 2018

View PDF